BlackRock Group’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$4.21M Buy
104,738
+33,500
+47% +$1.26M ﹤0.01% 1286
2016
Q3
$2.58M Buy
71,238
+4,264
+6% +$146K ﹤0.01% 1450
2016
Q2
$1.94M Buy
66,974
+4,829
+8% +$146K ﹤0.01% 1566
2016
Q1
$2.17M Buy
62,145
+4,920
+9% +$159K ﹤0.01% 1490
2015
Q4
$1.84M Buy
57,225
+855
+2% +$27.7K ﹤0.01% 1533
2015
Q3
$1.82M Buy
56,370
+343
+0.6% +$12.9K ﹤0.01% 1550
2015
Q2
$2.32M Sell
56,027
-247
-0.4% -$10.4K ﹤0.01% 1471
2015
Q1
$2.53M Sell
56,274
-4,503
-7% -$188K ﹤0.01% 1377
2014
Q4
$2.27M Buy
60,777
+10,872
+22% +$398K ﹤0.01% 1419
2014
Q3
$1.74M Sell
49,905
-6,538
-12% -$233K ﹤0.01% 1483
2014
Q2
$1.99M Sell
56,443
-13,971
-20% -$467K ﹤0.01% 1465
2014
Q1
$2.3M Sell
70,414
-702
-1% -$26.8K ﹤0.01% 1479
2013
Q4
$3M Buy
71,116
+6,336
+10% +$261K ﹤0.01% 1278
2013
Q3
$2.58M Buy
64,780
+10,290
+19% +$432K ﹤0.01% 1336
2013
Q2
$2.25M Buy
+54,490
New +$2.21M ﹤0.01% 1234

Other funds holding HAE

BlackRock Group's HAE Position: Q4 2016 in Review

BlackRock Group increased its Haemonetics (HAE) stake by 47% in Q4 2016, buying an estimated $1.26M and bringing the position to 104,738 shares worth $4.21M. The position accounts for ﹤0.01% of the portfolio, ranked #1286.

BlackRock Group first reported a position in HAE in Q2 2013 and has held it in 15 quarters since. 198 funds tracked by Wall St. Rank hold HAE as of Q4 2016.

  • BlackRock Group held 104,738 shares of Haemonetics worth $4.21M as of Q4 2016.
  • BlackRock Group bought 33,500 Haemonetics shares in Q4 2016, an estimated $1.26M.
  • Haemonetics made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #1286 holding.
  • BlackRock Group first reported a position in Haemonetics in Q2 2013 and has held it in 15 quarters since.
  • 198 funds tracked by Wall St. Rank held Haemonetics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.